Related Experiment Video
Updated: Jul 17, 2026
11:03
Subretinal Transplantation of Human Embryonic Stem Cell Derived-retinal Pigment Epithelial Cells into a Large-eyed Model of Geographic Atrophy
Published on: January 22, 2018
Triamcinolone pseudo-cataract
Arpita Jain1, Mandagere R Vishwanath, Stephen J Charles
1Royal Oldham Hospital, Oldham, UK.
Annals of Ophthalmology (Skokie, Ill.)
|January 4, 2007
Summary
Triamcinolone particles can form a pseudo-cataract on the lens after intravitreal injection for macular edema. These unusual deposits persisted for over six months in this case report.
Area of Science:
- Ophthalmology
- Retinal Diseases
- Pharmacology
Background:
- Macular edema secondary to non-ischemic central retinal vein occlusion is a common cause of vision loss.
- Intravitreal injections of corticosteroids, such as triamcinolone acetonide, are a standard treatment for this condition.
- While generally safe, corticosteroid injections can have ocular side effects.
Observation:
- A case report details a patient who developed a pseudo-cataract after a 2-mg intravitreal triamcinolone injection.
- The pseudo-cataract was characterized by the adherence of triamcinolone particles to the posterior lens surface.
- These deposits were noted to persist unusually long, beyond the typical resolution period.
Findings:
- The adherence of triamcinolone particles to the lens can mimic cataract formation.
- The persistence of these deposits for over six months is an atypical clinical observation.
- This highlights a potential, albeit rare, complication of intravitreal triamcinolone acetonide therapy.
Implications:
- Clinicians should be aware of the possibility of pseudo-cataract formation from triamcinolone particles.
- Extended persistence of these deposits may warrant further investigation or management considerations.
- This case contributes to the understanding of the long-term ocular effects of intravitreal corticosteroid injections.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:23Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...